Citations

Clear

479 citation(s) found for "Tobias, JS".

Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease
Uderhardt, Stefan , Ackermann, Jochen A. , Fillep, Tobias, Hammond, Victoria J., Willeit, Johann , Santer, Peter , Mayr, Manuel , Biburger, Markus , Miller, Meike , Zellner, Katie R. , Stark, Konstantin , Zarbock, Alexander , Rossaint, Jan , Schubert, Irene , Mielenz, Dirk , Dietel, Barbara , Raaz‐Schrauder, Dorette , Ay, Cihan , Gremmel, Thomas , Thaler, J. , Heim, Christian , Voehringer, David , Nadler, Jerry L. , Lee, James J. , Maßberg, Steffen , Schett, Georg , O’Donnell, Valerie B. , Krönke, Gerhard , Herrmann, Martin , Kiechl, Stefan , Schett, Georg , Krönke, Gerhard , Collins, Peter W. , Schabbauer, Gernot , Mackman, Nigel , Rauh, Manfred , Uderhardt, Stefan

Mayo Clinic

Journal of Experimental Medicine | May 31, 2017 | Volume: 214 | Issue: 7 | Pages: 2121-2138

10.1084/jem.20161070 | PMID 28566277 Get It

Blood coagulation is essential for physiological hemostasis but simultaneously contributes to thrombotic disease. However, molecular and cellular events controlling initiation and propagation of coagulation are still incompletely understood. In this study, we demonstrate an unexpected role of eosinophils during plasmatic coagulation, hemostasis, and thrombosis. Using a large-scale epidemiological approach, we identified eosinophil cationic protein as an independent and predictive risk factor for thrombotic events in humans. Concurrent experiments showed that eosinophils contributed to intravascular thrombosis by exhibiting a strong endogenous thrombin-generation capacity that relied on the enzymatic generation and active provision of a procoagulant phospholipid surface enriched in 12/15-lipoxygenase–derived hydroxyeicosatetraenoic acid–phosphatidylethanolamines. Our findings reveal a previously unrecognized role of eosinophils and enzymatic lipid oxidation as regulatory elements that facilitate both hemostasis and thrombosis in response to vascular injury, thus identifying promising new targets for the treatment of thrombotic disease.
Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis
Arkenau, Hendrik‐Tobias , Kubicka, Stefan, Seufferlein, Thomas , Reichardt, Peter , Freier, Werner , Porschen, Rainer, Schmoll, Hans‐Joachim , Graeven, Ullrich , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3546-3546

10.1200/jco.2004.22.90140.3546 Get It

Abstract PD2-03: Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer
Lei, JT, Shao, Juntao , Zhang, J, Iglesia, Michael D. , Cao, Jin , He, Xiaoping , Kosaka, Yoshimasa , Schmidt, Cecilia, Matsunuma, Ryoichi , Haricharan, Svasti , Crowder, RJ, Hoog, J, Phommaly, Chanpheng, Gonçalves, Rodrigo , Ramalho, Susana , Lai, W-C, Rogers, Anna , Tobias, Ethan, Parikh, Poojan A., Davies, S. J. , Hunt, Katie N. , Watson, Mark , Hoadley, KA, Thompson, Alastair M. , Chen, X , Perou, CM, Creighton, CJ, Maher, CA, Ellis, MJ, Maher, Christopher G. , Chan, David W. , Hampton, Oliver , Ma, C, Suman, Vera J. , Watson, M, Hoadley, Katherine A.

Mayo Clinic

Cancer Research | March 1, 2017 | Volume: 77 | Issue: 4_Supplement | Pages: PD2-03-PD2-03

10.1158/1538-7445.sabcs16-pd2-03 Get It

Abstract Background. We previously reported an alternative ESR1 somatic gain-of-function chromosomal translocation event in a patient presenting with aggressive, endocrine therapy resistant estrogen receptor (ER) positive disease, producing an in-frame fusion gene consisting of N-terminal ESR1 and the C-terminus of the Hippo pathway coactivator YAP1 (ESR1-YAP1). We recently identified another ESR1 fusion through RNA sequencing (RNA-seq) in advanced stage ER+ disease from a chest wall recurrence in a male patient that was refractory to multiple lines of treatment. Two examples of fusions discovered in primary breast cancer samples include ESR1 fused in-frame to C-terminal sequences from NOP2 (ESR1-NOP2), identified in a resistant cohort from a RNA-seq screen focused on 81 primary breast cancers from aromatase inhibitor clinical trials, and a second ESR1 fusion, fused in-frame to the entire coding sequence of POLH (ESR1-POLH), that was identified from RNA-seq analysis of 728 Cancer Genome Atlas breast samples. This current study extends our previous characterization of ESR1-YAP1 by comparing functional and pharmacological properties of these three additional ESR1 gene fusion events of both early stage and advanced breast cancers. Methods. In vitro and in vivo experiments were conducted to test ESR1 fusions to induce therapeutic resistance, and metastasis. The transcriptional and binding properties of each fusion was also examined. Pharmacological inhibition with Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, was utilized to assess drug sensitivity in ESR1 fusion containing breast cancer cells and in a patient derived xenograft (PDX) model expressing ESR1-YAP1 (WHIM18). Results. The YAP1 and PCDH11x fusions conferred estrogen-independent and fulvestrant-resistant growth. Immunohistochemistry revealed significantly higher numbers of ER+ cells in lungs of mice xenografted with T47D cells expressing the YAP1 and PCDH11x fusions compared to YFP control, NOP2 and POLH fusions. Results from ChIP-seq and microarray studies suggest that these two fusions promote proliferation and metastasis through genomic action by binding estrogen response elements (ERE) and subsequent gene activation. We thereby define these fusions as “canonical” fusions compared to “non-canonical” NOP2 and POLH fusions, which demonstrated dramatically decreased genomic binding ability. The non-canonical fusions induced genes associated with basal-like breast cancer and promoted HER2, EGFR, and MAPK gene expression signatures in contrast to genes associated with cell cycle/proliferation induced by canonical fusions. The proliferative ability of canonical fusion-containing ER+ cells was inhibited by Palbociclib in a dose-dependent manner. In vivo WHIM18 tumors in mice fed with Palbociclib-containing chow demonstrated significantly reduced tumor volume, growth rate, and weight compared to tumors in mice on control chow. Conclusions. In-frame ERE activating canonical fusions occur in end-stage drug resistant advanced breast cancer and can be added to ESR1 point mutations as a class of recurrent somatic mutation that may cause acquired resistance. Growth induced by these fusions can be antagonized by Palbociclib and is potentially clinically helpful. Citation Format: Lei JT, Shao J, Zhang J, Iglesia M, Cao J, Chan DW, He X, Kosaka Y, Schmidt C, Matsunuma R, Haricharan S, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Lai W-C, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Chen X, Perou CM, Creighton CJ, Maher C, Ellis MJ. Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD2-03.
Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis
Arkenau, Hendrik‐Tobias , Kubicka, Stefan, Kretzschmar, Albrecht , Freier, Werner , Seufferlein, Thomas , Hinke, Axel , Porschen, Rainer, Schmoll, Hans‐Joachim , Graeven, Ullrich , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3507-3507

10.1200/jco.2005.23.16_suppl.3507 Get It

Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders
Wolff, Markus , Johannesen, Katrine M. , Hedrich, Ulrike B. S. , Masnada, Silvia , Rubboli, Guido , Gardella, Elena , Lesca, Gaëtan , Ville, Dorothée , Milh, Mathieu , Villard, Laurent , Afenjar, Alexandra , Chantot‐Bastaraud, Sandra , Mignot, Cyril , Lardennois, Caroline, Nava, Caroline , Schwarz, Niklas , Gérard, Marion , Perrin, Laurence, Doummar, Diane , Miranda, María J., Hempel, Maja , Brilstra, Eva H. , Knoers, Nine, Verbeek, Nienke E., Kempen, Marjan van, Braun, Kees P. J. , Mancini, Grazia M.S. , Biskup, Saskia, Hörtnagel, Konstanze , Döcker, Miriam, Bast, Thomas , Loddenkemper, Tobias , Baumeister, Friedrich, Fazeli, Walid , Striano, Pasquale, Dilena, Robertino , Fontana, Elena , Zara, Federico , Kurlemann, Gerhard, Klepper, Joerg , Thoene, Jess G. , Arndt, Daniel H. , Deconinck, Nicolas , Schmitt‐Mechelke, Thomas , Muhle, Hiltrud, Wical, Beverly, Finetti, C., Brückner, Reinhard , Pietz, Joachim, Golla, G., Jillella, Dinesh , Linnet, Karen Markussen, Charles, Perrine , Moog, Ute , Õiglane‐Shlik, Eve, Mantovani, John F., Park, Kristen , Deprez, Marie, Lederer, Damien , Mary, Sandrine, Scalais, Emmanuel , Selim, Laila , Coster, Rudy Van , Lagae, Lieven , Nikanorova, Marina , Hjalgrim, Helle , Korenke, Georg-Christoph , Trivisano, Marina , Specchio, Nicola , Ceulemans, Berten , Dorn, Thomas, Helbig, Katherine L. , Hardies, Katia, Stamberger, Hannah , Jonghe, Peter De, Weckhuysen, Sarah , Kluger, Gerhard , Møller, Rikke S. , Wong-Kisiel, Lily, Auvin, Stéphane , Kempen, Marjan J. A. van, Wong‐Kisiel, Lily C. , Maier, Oliver , Lemke, Johannes R. , Krägeloh‐Mann, Ingeborg , Helbig, Ingo , Lerche, Holger , Loddenkemper, Tobias , Villard, Laurent , Rubboli, Guido , Schwarz, Niklas , Specchio, Nicola , Gardella, Elena , Lesca, Gaetan , Møller, Rikke S , Jillella, Dinesh V

Mayo Clinic

Brain | February 23, 2017 | Volume: 140 | Issue: 5 | Pages: 1316-1336

10.1093/brain/awx054 | PMID 28379373 Get It

Senescent intimal foam cells are deleterious at all stages of atherosclerosis
Childs, Bennett G. , Baker, Darren J. , Wijshake, Tobias , Conover, Cheryl A. , Campisi, Judith , Deursen, Jan M. van , Baker, Darren J

Mayo Clinic

Science | October 27, 2016 | Volume: 354 | Issue: 6311 | Pages: 472-477

10.1126/science.aaf6659 | PMID 27789842 Get It

Wreaking havoc while (growth-)arrested Cells enter a state of senescence in response to certain stresses. Studying mouse models, Childs et al. examined the role of senescent lipid-loaded macrophages (so-called “foam cells”) in the pathogenesis of atherosclerosis. At early stages of atherosclerosis, senescent foam cells promoted the expression of inflammatory cytokines. At later stages, they promoted the expression of matrix metalloproteases implicated in the rupture of atherosclerotic plaque, which can lead to blood clots. Experimental removal of the senescent cells had beneficial effects at both stages of the disease. Science , this issue p. 472
Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21
Wang, Zhaoming , Obazee, Ofure , Jia, Jinping , Childs, Erica J., Hoskins, Jason W. , Figlioli, Gisella , Collins, Irene , Chung, Charles C., Hautman, Christopher, Arslan, Alan A. , Bracci, Paige M. , Buring, Julie E. , Gallinger, Steven , Goodman, Gary E. , Goodman, Phyllis J. , Kamineni, Aruna , Kolonel, Laurence N. , Kulke, Matthew H. , Malats, Núria , Olson, Sara H. , Sesso, Howard D. , Visvanathan, Kala , Zheng, Wei , Abnet, Christian C. , Andreotti, Gabriella , Bueno-de-Mesquita, H. Bas, Basso, Daniela , Berndt, Sonja I. , Brenner, Hermann , Burdette, Laurie , Campa, Daniele , Caporaso, Neil E. , Capurso, Gabriele , Cavestro, Giulia Martina , Costello, Eithne , Elena, Joanne W. , Boggi, Ugo , Gaziano, J. Michael , Giovannucci, Edward L. , Gross, Myron D., Haiman, Christopher A. , Hassan, Manal M. , Helzlsouer, Kathy J., Hu, Nan , Hunter, David J., Iskierka‐Jazdzewska, Elżbieta , Jenab, Mazda , Klein, Eric A. , Krogh, Vittorio , Kupčinskas, Juozas , Kurtz, Robert C. , Landi, Maria Teresa , Mambrini, Andrea , Neale, Rachel Ε. , Oberg, Ann L. , Patel, Alpa V. , Peeters, Petra H., Peters, Ulrike , Pezzilli, Raffaele , Porta, Miquel , Purdue, Mark P. , Quirós, J. Ramón , Ríboli, Elio , Rothman, Nathaniel , Scarpa, Aldo , Scélo, Ghislaine , Strobel, Oliver , Małecka‐Panas, Ewa , Tavano, Francesca , Travis, Ruth C. , Thornquist, Mark, Tjønneland, Anne , Trichopoulos, Dimitrios, Vashist, Yogesh K. , Vodička, Pavel , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Jacobs, Eric J. , Li, Donghui , Fuchs, Charles S. , Hoover, Robert N. , Hartge, Patricia, Petersen, Gloria M. , Stolzenberg-Solomon, Rachael S., Wolpin, Brian M. , Kraft, Peter , Canzian, Federico , Ámundadóttir, Laufey T. , Zhang, Mingfeng , Mocci, Evelina , Freeman, Laura E. Beane , Duell, Eric J. , Giles, Graham G. , White, Emily , Albanes, Demetrius , Brais, Lauren K , Boutron‐Ruault, Marie‐Christine , Bijlsma, Maarten F. , Cotterchio, Michelle , Gazouli, Maria , Goggins, Michael , Kaaks, Rudolf , Key, Tim , Khaw, Kay‐Tee , Kogevinas, Manolis , Kupcinskas, Juozas , Landi, Stefano , Marchand, Loı̈c Le , Männistö, Satu , Milne, Roger L. , Panico, Salvatore , Shu, Xiao‐Ou , Silverman, Debra T. , Souček, Pavel , Sund, Malin , Taylor, Philip R. , Tobias, Geoffrey S. , Yu, Kai , Kooperberg, Charles , Risch, Harvey A. , Chanock, Stephen Jacob , Klein, Alison P. , Amundadottir, Laufey , Malats, Nuria , Arslan, Alan A , Canzian, Federico , Tjønneland, Anne , Wactawski-Wende, Jean , Travis, Ruth C , Wang, Zhaoming , Abnet, Christian C , Visvanathan, Kala , Klein, Eric A , Brenner, Hermann , Strobel, Oliver , Jenab, Mazda , Kraft, Peter , Zheng, Wei , Iskierka-Jazdzewska, Elżbieta , Riboli, Elio , Vodicka, Pavel , Neale, Rachel E , Porta, Miquel , Zeleniuch-Jacquotte, Anne , Hoskins, Jason W , Tavano, Francesca

Mayo Clinic

Oncotarget | September 16, 2016 | Volume: 7 | Issue: 41 | Pages: 66328-66343

10.18632/oncotarget.11041 | PMID 27579533 Get It

Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort
Leister, Erin, Coryell, Jason , Nickels, Katherine , Ryan, Nicole, Juarez‐Colunga, Elizabeth , Gaillard, William D. , Mytinger, John R. , Berg, Anne T. , Millichap, J Gordon , Nordli, Douglas R. , Joshi, Sucheta M. , Shellhaas, Renée A. , Loddenkemper, Tobias , Dlugos, Dennis , Sullivan, Joseph , Hartman, Adam L. , Kossoff, Eric H. , Grinspan, Zachary M. , Hamikawa, Lorie, Wusthoff, Courtney J. , Novotny, Edward J. , Yozawitz, Elissa , Millichap, John , Knupp, Kelly G. , Wirrell, Elaine , Shellhaas, Renée A , Novotny, Edward J , Gaillard, William D , Loddenkemper, Tobias , Yozawitz, Elissa G , Berg, Anne T , Grinspan, Zachary , Nickels, Katherine C , Coryell, Jason , Wusthoff, Courtney J

Mayo Clinic

Epilepsia | September 12, 2016 | Volume: 57 | Issue: 11 | Pages: 1834-1842

10.1111/epi.13557 | PMID 27615012 Get It

Summary Objective Infantile spasms ( IS ) represent a severe epileptic encephalopathy presenting in the first 2 years of life. Recommended first‐line therapies (hormonal therapy or vigabatrin) often fail. We evaluated response to second treatment for IS in children in whom the initial therapy failed to produce both clinical remission and electrographic resolution of hypsarhythmia and whether time to treatment was related to outcome. Methods The National Infantile Spasms Consortium established a multicenter, prospective database enrolling infants with new diagnosis of IS. Children were considered nonresponders to first treatment if there was no clinical remission or persistence of hypsarhythmia. Treatment was evaluated as hormonal therapy (adrenocorticotropic hormone [ ACTH ] or oral corticosteroids), vigabatrin, or “other.” Standard treatments (hormonal and vigabatrin) were compared to all other nonstandard treatments. We compared response rates using chi‐square tests and multivariable logistic regression models. Results One hundred eighteen infants were included from 19 centers. Overall response rate to a second treatment was 37% (n = 44). Children who received standard medications with differing mechanisms for first and second treatment had higher response rates than other sequences (27/49 [55%] vs. 17/69 [25%], p < 0.001). Children receiving first treatment within 4 weeks of IS onset had a higher response rate to second treatment than those initially treated later (36/82 [44%] vs. 8/34 [24%], p = 0.040). Significance Greater than one third of children with IS will respond to a second medication. Choosing a standard medication ( ACTH , oral corticosteroids, or vigabatrin) that has a different mechanism of action appears to be more effective. Rapid initial treatment increases the likelihood of response to the second treatment.
Abstract 1260: Polymerase kappa determines the sensitivity of MTH1 inhibitors to cisplatin-resistant cell
Hurley, Rachel M. , Herr, Patric, Koolmeister, Tobias, Jaques, Sylvain, Höglund, Andreas , Scobie, Martin , Kaufmann, Scott H. , Weroha, S. John , Hendrickson, Andrea Wahner, Sanjiv, Kumar , Gad, Helge , Rudd, Sean G. , Herr, Patrick , Calderón‐Montaño, José Manuel , Mortusewicz, Oliver , Burgos‐Morón, Estefanía , Lee, Te‐Chang , Berglund, Ulrika Warpman , Helleday, Thomas , Kaufmann, Scott H

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 1260-1260

10.1158/1538-7445.am2016-1260 Get It

Abstract Resistance is one the main reason for overall decrease in survival of cancer patient treated with cisplatin in different types of cancer. Cisplatin kills cancer cells by various mechanisms, but mainly through formation of inter- and intra stand crosslinks of DNA. Different types of translesion polymerase including Polymerase kappa (POLK) are involved in repair of DNA lesions. We observed high expression levels of POLK in cisplatin resistant bladder and ovarian cancer cells compared to parental cells. Due to its low proof-reading activity POLK can incorporate 8-oxo-dGTP into DNA. The MTH1 protein (Nudix hydrolase- NUDT1) sanitizes oxidized dNTP pools to prevent incorporation of damaged bases during DNA replication. Recently we have generated MTH1 inhibitors that damage the DNA and induce cancer specific cell death through incorporation of more oxidized dNTPs. We found cisplatin resistant bladder cancer cells (NTUB1/P) were more sensitive to MTH1 inhibitors in comparison to parental NTUB1 cells. As POLK is involved in incorporation of 8-oxo-dGTP into DNA, we hypothesized that high expression levels of POLK in cisplatin resistant cells make them more sensitive to MTH1 inhibitors as more 8-oxo-dGTP would be incorporated into DNA, resulting in more DNA damage and cell death in comparison to parental cells. Indeed, we observes higher induction of cleaved-PARP, γH2AX, cleaved-Caspase 3 and more annexin v positive cells in cisplatin resistant NTUB1/P cells in comparison to parental NTUB1 cells upon treatment with MTH1 inhibitors. MTH1 inhibitor also significantly delays the NTUB1/P xenograft tumor growth in comparison to vehicle treatment in immunosuppressive mice. Knocking down POLK in cisplatin resistant NTUB1/P cells by siRNA resulted in decreased incorporation of 8-oxo-dGTP and sensitivity to MTH1 inhibitors compared to non target control cells. Overexpression of POLK in NTUB1 and NTUB1/P cells results in further sensitization to MTH1 inhibitors. In conclusion elevated levels of POLK in cisplatin resistance cells determines increased sensitivity towards MTH1 inhibitors. Thus MTH1 inhibitors can be a potential promising therapy for the treatment of cisplatin resistant tumors in patients. Citation Format: Kumar Sanjiv, Helge Gad, Sean Rudd, Rachel Hurley, Patric Herr, José Manuel Calderón Montaño, Oliver Mortusewicz, Tobias Koolmeister, Sylvain Jaques, Estefanía Burgos Morón, Andreas Hoglund, Te-Chang Lee, Martin Scobie, Scott Kaufmann, John Weroha, Ulrika Warpman Berglund, Andrea Wahner Hendrickson, Thomas Helleday. Polymerase kappa determines the sensitivity of MTH1 inhibitors to cisplatin-resistant cell. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1260.